Retrospective analysis of febrile neutropenia risk after chemotheraphy with nomogram in solid cancer patients

Objective: Febrile neutropenia is an oncological emergency with is high risk mortality in patient receiving chemotherapy. The purpose of this project, to analysis the nomogram which use to calculate febrile neutropenia risk, to measure all solid cancers with using nomogram which is previously limited developed, and use nomogram is intended to adapt to daily clinical practice. Method: Patients enrolled retrospectively the study, who had cancer diagnosis and chemotherapy regimen administered at between 2014-2016 years. Patient data were obtained with scan of file. Risk of each patient was determined by nomogram. All diagnosis and treatment evaluated without selection. Properties of used chemotherapy and each of treatment cure were evaluated by separately. Determined factors that meaningful in one variant was included logistic regression test. Results: 895 patients were included in study. The patient was %50,8 (455) male , %49,2 (440) female. The median age was 56,66±11,21, min-max 22-86, median was 57,5. 1032 cycles of these patients were evaluated the study. According to analysed risk for febrile neutropenia, the highest relative risk found of how many steps the patients received chemotherapy. OR: 1,696 (%95 CI=1,263-2,276) and the data were statistically significant (p=0,000). In addition, parameters that dose reduction, LDH value and using GCSF were found independent predictive factors on febrile neutropenia (p=0,000). Conclusion: This nomogram can be use with a tool to calculate the risk ratio of febrile neutropenia and to reduce to mortality and morbidity rate depending on febrile neutropenia in oncology patients. Key Words: Febrile neutropenia, nomogram, chemotherapy